TNSN96025A1 - NEW ORAL PHARMACEUTICAL PRESENTATION - Google Patents

NEW ORAL PHARMACEUTICAL PRESENTATION

Info

Publication number
TNSN96025A1
TNSN96025A1 TNTNSN96025A TNSN96025A TNSN96025A1 TN SN96025 A1 TNSN96025 A1 TN SN96025A1 TN TNSN96025 A TNTNSN96025 A TN TNSN96025A TN SN96025 A TNSN96025 A TN SN96025A TN SN96025 A1 TNSN96025 A1 TN SN96025A1
Authority
TN
Tunisia
Prior art keywords
presentation
formulation
oral pharmaceutical
pharmaceutical presentation
new oral
Prior art date
Application number
TNTNSN96025A
Other languages
French (fr)
Inventor
Depui Helene
Rosinski Adam
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9500422A external-priority patent/SE9500422D0/en
Application filed by Astra Ab filed Critical Astra Ab
Publication of TNSN96025A1 publication Critical patent/TNSN96025A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

UNE PRESENTATION PHARMACEUTIQUE POUR ADMINISTRATION PAR VOIE BUCCALE COMPRENANT UN INHIBITEUR DE POMPE PROTONIQUE SENSIBLE A L'ACIDE ET UN OU PLUSIEURS COMPOSES ANTIBACTERIENS DANS UNE FORMULATION FIXE. LA FORMULATION FIXE EST DESTINEE A L'EMPLOI PAR VOIE BUCCALE ET SOUS LA FORME DE COMPRIMES A ENROBAGE A DELITEMENT ENTERIQUE ; SOUS LA FORME D'UNE GELULE; OU SOUS LA FORME DE COMPRIMES A UNITES MULTIPLES. LA PRESENTATION A UNITES MULTIPLES EST CELLE QUI EST PREFEREE. LA NOUVELLE FORMULATION A DOSE FIXE EST PARTICULIEREMENT UTILE DANS LE TRAITEMENT D'AFFECTIONS ASSOCIEES AUX INFECTIONS AU HELICOBACTER.A PHARMACEUTICAL PRESENTATION FOR ORAL ADMINISTRATION COMPRISING AN ACID SENSITIVE PROTONIC PUMP INHIBITOR AND ONE OR MORE ANTIBACTERIAL COMPOUNDS IN A FIXED FORMULATION. THE FIXED FORMULATION IS INTENDED FOR ORAL USE AND IN THE FORM OF DELICALLY ENTERIC COATED TABLETS; IN THE FORM OF A CAPSULE; OR IN THE FORM OF MULTIPLE UNIT TABLETS. THE PRESENTATION IN MULTIPLE UNITS IS THAT PREFERRED. THE NEW FIXED DOSE FORMULATION IS ESPECIALLY USEFUL IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH HELICOBACTER INFECTIONS.

TNTNSN96025A 1995-02-06 1996-02-05 NEW ORAL PHARMACEUTICAL PRESENTATION TNSN96025A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9500422A SE9500422D0 (en) 1995-02-06 1995-02-06 New oral pharmaceutical dosage forms

Publications (1)

Publication Number Publication Date
TNSN96025A1 true TNSN96025A1 (en) 2005-03-15

Family

ID=47598445

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN96025A TNSN96025A1 (en) 1995-02-06 1996-02-05 NEW ORAL PHARMACEUTICAL PRESENTATION

Country Status (3)

Country Link
KR (1) KR100399524B1 (en)
TN (1) TNSN96025A1 (en)
YU (1) YU7396A (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128140A (en) * 1991-01-14 1992-07-07 The Procter & Gamble Company Swallowable pharmaceutical compositions

Also Published As

Publication number Publication date
YU7396A (en) 1998-08-14
KR100399524B1 (en) 2004-04-13

Similar Documents

Publication Publication Date Title
TNSN98059A1 (en) SELECTIVE COX-2 INHIBITOR COMPOUNDS, ANTI-INFLAMMATORY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
Shaw Causes and control of dental caries
TNSN96024A1 (en) NEW PHARMACEUTICAL COMBINATION
AU6770490A (en) Solid pharmaceutical compositions containing cimetidine
BE901667A (en) ANALGESIC AND ANTI-INFLAMMATORY COMPOSITION BASED ON DIPHENHYDRAMINE, THEIR PREPARATION AND THEIR USE.
DZ1078A1 (en) Pharmaceutical formulation of acid labile substance for oral administration.
CA2134196A1 (en) Pharmaceutical preparation and process for its manufacture
TNSN97139A1 (en) DERIVATIVES OF ARYLSULFONYLAMINOHYDROXAMIC ACIDS
DE3686936D1 (en) ENTERAL DELIVERY SYSTEM ACTIVE ON THE TARGET ORGAN.
NO975218L (en) Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
DE68920578D1 (en) Various types of pharmaceuticals containing orally administered cellulose ether with controlled release of active ingredients.
BE899885A (en) NAPROXEN AND NAPROXEN SODIUM TABLETS WITH CONTROLLED RELEASE.
KR950031069A (en) How to suppress bone loss and lower serum cholesterol
TNSN98229A1 (en) EXTENDED RELEASE ORAL PHARMACEUTICAL FORMULATION
RU94026283A (en) Pharmaceutical compound
JPH01279838A (en) Lysozyme chloride-containing plaster for gingivitis and pyorrhea
BE901073A (en) ANTIDIURETIC COMPOSITION FOR ORAL USE.
IT1256697B (en) MEDICATIONS TO TREAT INFLAMMATORY CONDITIONS OR ANALGESIA.
KR910014124A (en) Swallowable Dosage Units Containing Colloidal Bismuth Subcitrate (CBS)
IT1238072B (en) PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ORAL ADMINISTRATION OF CALCITONIN
TNSN96025A1 (en) NEW ORAL PHARMACEUTICAL PRESENTATION
IT8820172A0 (en) AMIDES OF CYCLOMETHYLEN_1,2_DICARBOXYLIC ACIDS THERAPEUTIC SUITABILITY, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
BE1002295A5 (en) DRUGS.
BE1002255A5 (en) DRUGS.
FR2363324A1 (en) AQUEOUS OR HYDROALCOOLIC STABLE SOLUTIONS OF PERFUMED ESSENCES OR OIL SOLUBLE MEDICINAL PRODUCTS